
# BEST AVAILABLE COPY

### PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY WRITTEN OPINION OF THE see form PCT/ISA/220 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION see form PCT/ISA/220 See paragraph 2 below International application No. International filing date (day/month/year) Priority date (day/month/year) PCT/EP2004/007820 09.07.2004 11.07.2003 International Patent Classification (IPC) or both national classification and IPC C07J3/00, A61K31/56, A61P5/44 Applicant **GLAXO GROUP LIMITED** 1. This opinion contains indications relating to the following items: Box No. 1 Basis of the opinion ☑ Box No. II Priority Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability ☐ Box No. IV Lack of unity of invention Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial ☑ Box No. V applicability; citations and explanations supporting such statement ☐ Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220.



Authorized Officer

European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465

Samsam Bakhtiary, M Telephone No. +49 89 2399-8556



IAP20 RGS 1 11 JAN 2005
International application No.
PCT/EP2004/007820

### WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

_	Box N	o. I Basis of the opinion	
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it was field, unless otherwise indicated under this item.		
	la	nis opinion has been established on the basis of a translation from the original language into the following nguage , which is the language of a translation furnished for the purposes of international search nder Rules 12.3 and 23.1(b)).	
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:		
	a. type of material:		
		a sequence listing	
		table(s) related to the sequence listing	
	b. format of material:		
		in written format	
		in computer readable form	
c. time of filing/furnishing:		of filing/furnishing:	
		contained in the international application as filed.	
		filed together with the international application in computer readable form.	
		furnished subsequently to this Authority for the purposes of search.	
3.	ha CC	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto as been filed or furnished, the required statements that the information in the subsequent or additional spies is identical to that in the application as filed or does not go beyond the application as filed, as opropriate, were furnished.	

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/EP2004/007820

Box No. II		Priority			
1. 🖾	The following document has not been furnished:				
	×	copy of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(a)).			
		translation of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(b)).			
	Consequently it has not been possible to consider the validity of the priority claim. This opinion has nevertheless been established on the assumption that the relevant date is the claimed priority date.				
2. 🗆	This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43 <i>bis</i> .1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.				

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/EP2004/007820

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:					
☐ the entire international application,	the entire international application,				
☑ claims Nos. 8	claims Nos. 8				
because:					
	the said international application, or the said claims Nos. 8 only regarding industrial applicability relate to the following subject matter which does not require an international preliminary examination (specify):				
see separate sheet					
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
the claims, or said claims Nos. are could be formed.					
□ no international search report has	no international search report has been established for the whole application or for said claims Nos.				
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
the written form	has not been furnished				
	does not comply with the standard				
the computer readable form	has not been furnished				
	does not comply with the standard				
the tables related to the nucleotide not comply with the technical requi	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.				
☐ See separate sheet for further deta	uils				

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/EP2004/007820

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-9

1-9

1-8

No: Claims

Inventive step (IS)

Yes: Claims

No: Claims

Industrial applicability (IA)

Yes: Claims

No: Claims 9

2. Citations and explanations

see separate sheet

### Box No. VII Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

### Box No. Viii Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet



# IAP20 Rec'd Pariston 11 JAN 2006

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

PCT/EP2004/007820

### Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claim 8 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

### Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- 1. Reference is made to the following documents:
  - D1: WO 02/00679 A (NOVARTIS ERFIND VERWALT GMBH; NOVARTIS AG (CH); BEATTIE DAVID (GB); C) 3 January 2002 (2002-01-03)
  - D2: GB-A-1 514 476 (GLAXO LAB LTD) 14 June 1978 (1978-06-14)
  - D3: US-A-3 856 828 (PHILLIPPS G ET AL) 24 December 1974 (1974-12-24)
  - D4: UENO H ET AL: "Synthesis and evaluation of antiinflammatory activities of a series of corticosteroid 17.alpha.-esters containing a functional group"

    JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL

    SOCIETY. WASHINGTON, US, vol. 34, no. 8, 1 August 1991 (1991-08-01), pages 2468-2473, XP002086576 ISSN: 0022-2623

### 2. Novelty

The claimed subject matter is concerned with one specific steroid compound. None of the documents of the search report disclose such compound. The claimed subject matter can be considered as novel.

### 3. Inventive step

Document D1, which is considered to represent the most relevant state of the art, discloses (cf. examples 14,24 and claim 1) a steroid from which the subject-matter of claim 1 differs (at least one feature) in that cyano-ester on position 17 of ring system

instead of methyl-ester. Beside this, other structural features are different (in total 3 different technical feature).

The problem to be solved by the present invention may therefore be regarded as to provide a novel steroid useful as anti-inflammatory.

None of the documents cited in the search report neither alone or combined together would have led the skilled person to this specific steroid as claimed and foresee that such compound would still exert anti-inflammatory activities.

The claimed subject matter can be considered as inventive.

### Re Item VII

### Certain defects in the international application

Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1-D4 is not mentioned in the description, nor are these documents identified therein.

Even though these documents are cited as A category in the search report, they should be mentioned in the description because no other prior art have been cited.

### Re Item VIII

### Certain observations on the international application

For the assessment of the present claim 8 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

### IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.